This article from Coma et al. shows that a salicylic acid derivative Triflusal, a platelet aggregation inhibitor and irreversible inhibitor of COX-1, can correct defects in axonal curvature and cognition in an AD transgenic mouse model (Tg2576) (Coma et al., 2010). Here we discuss the controversy over the role of COX-1 in AD, which has not been considered carefully in part due to the presumed adverse gastrointestinal effects of COX-1 antagonism. However, recent clinical data from this group as well as other groups challenges this assumption that COX-1 antagonism will be associated with side effects. Most importantly this article raises critical questions about the role of COX-1, versus COX-2 versus both in Aβ pathogenesis. The animal model data in this article as well as the recently published trial data suggest that COX-1 may play an important role in early pathogenesis and should not be ignored as a potential target for early intervention.
The salicylic acid derivative Triflusal, a platelet aggregation inhibitor and irreversible inhibitor of COX-1, was effective in reducing cognitive deficits and indices of neurodegeneration. As with other NSAID effects observed in animal models, longer duration of Triflusal treatment appeared more effective, exerting a greater impact on reducing dense cored-plaque load and associated, glial cell proliferation, pro-inflammatory cytokine levels and abnormal axonal curvature, and the better the correction of cognitive deficits. The small Triflusal effects on amyloid burden (reducing dense cored plaques but not total burden) was somewhat surprising, considering that mixed COX inhibitors, including ibuprofen, have been reported to have a much more pronounced effect on reducing amyloid burden in AD models, provided intervention was pre-pathology and long duration (Choi et al., 2009; Heneka et al., 2005; Jantzen et al., 2002; Lim et al., 2000 Lim et al., , 2001 McKee et al., 2008; Morihara et al., 2005; Weggen et al., 2001; Yan et al., 2003) . Indomethacin, which like Triflusal, has more specificity for COX-1, exerted a similarly weak (but significant) antiamyloid effect reducing amyloid burden by 20%. In contrast, NCX-2216, nitro-S-flurbiprofen (also preferential COX-1) had an intermediate effect on reducing amyloid burden (Jantzen et al., 2002) . This may indicate that some of the anti-Aβ effects of mixed COX inhibitors like ibuprofen, indomethacin and flurbiprofen also benefit from pleiotropic actions including γ-secretase modulation (Weggen et al., 2001) , anti-aggregation (Agdeppa et al., 2002) and share significant COX-related mechanisms involving cytokine modulation (e.g. phospholipase A2, inducible nitric oxide synthase, interleukin-1, and α-1 anti-chymotrypsin) (Morihara et al., 2005) .
Trials in MCI or AD using a drug selective for COX-2 such as rofecoxib clearly failed (Aisen et al., 2008) . Ultimately, COX-2 inhibitors have not worked in clinical trials after onset of cognitive deficits, for example, the COX-2 inhibitor rofecoxib was even associated with increased AD in a trial with MCI patients (Aisen et al., 2008) . Similarly, a COX-2 inhibitor did not work for primary prevention in the ADAPT which was enriched with subjects with first degree relatives of AD patients (Laino, 2009). The anti-inflammatory steroid agent prednisolone failed (Aisen et al., 2000) , which may relate to a known effect of glucocorticoids in inhibiting COX-2 in astrocytes (O'Banion et al., 1996) .
Non selective COX inhibitors such as indomethacin (Rogers et al., 1993) and diclofenac (Scharf et al., 1999) showed preferential inhibition of COX-1 and possible positive clinical findings in AD trials. These "somewhat positive" trials were underpowered and full of safety issues including low tolerability. But with the positive results and good safety trial with Triflusal (Gomez-Isla et al., 2008) , does that mean we should dismiss COX-2 as a target for prevention? Well the answer to that question requires a better understanding of stagedependent pathogenesis. For example, COX-2 is elevated early in AD brain (Hoozemans et al., 2008) . In AD models, COX-2 inhibitors can correct early deficits in LTP and cognition (Kotilinek et al., 2008) and early intervention trials (preMCI) with COX-2 specific inhibitor celecoxib showed a cognitive benefit with mild memory complaints 
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